Research programme: cannabinoid prodrugs - Vitality Biopharma

Drug Profile

Research programme: cannabinoid prodrugs - Vitality Biopharma

Alternative Names: Cannabinoid glycosides - Vitality Biopharma; Cannabinosides - Vitality Biopharma

Latest Information Update: 21 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vitality Biopharma
  • Class Antiepileptic drugs; Cannabinoids
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Epilepsy; Guillain-Barre syndrome; Huntington's disease; Inflammatory bowel diseases; Pain; Schizophrenia; Ulcerative colitis

Most Recent Events

  • 19 Jul 2017 Preclinical trials in Ulcerative colitis in USA (unspecified route)
  • 19 Jul 2017 Pharmacodynamics data from preclinical studies in Inflammatory bowel disease and Ulcerative colitis released by Vitality Biopharma
  • 19 Jul 2017 Vitality Biopharma plans a clinical trial for Inflammatory bowel disease and Ulcerative colitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top